GlassScriptPhysician profile
Gabrielle Weaver
NPI 1881341394
$3,742.55
in general payments reported to CMS, 2019-2025
27 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $390 · 2024: $1,388 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,563.56 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $463.74 | 2023-2025 | Tremfya |
| Abbvie INC. | $415.14 | 2023-2025 | |
| Pfizer INC. | $361.95 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $343.55 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $337.22 | 2023-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $318.54 | 2024-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $265.99 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $213.03 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $196.22 | 2023-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $139.70 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Journey Medical Corporation | $110.34 | 2025 | |
| Ucb, INC. | $87.81 | 2024-2025 | Bimzelx |
| Smith+Nephew, INC. | $79.00 | 2023-2024 | Collagenase Santyl |
| Regeneron Pharmaceuticals, INC. | $67.84 | 2025 | Dupixent |
| Incyte Corporation | $54.06 | 2023-2025 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.90 | 2024-2025 | Sotyktu |
| Genentech USA, INC. | $32.68 | 2024 | Erivedge |
| Amgen INC. | $29.65 | 2024 | Otezla |
| Genzyme Corporation | $29.30 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.19 | 2024 | Cabtreo |
| Organon LLC | $23.39 | 2025 | Vtama |
| Convatec INC. | $22.49 | 2024 | |
| Paratek Pharmaceuticals, INC. | $21.90 | 2025 | Nuzyra |
| Merz North America, INC. | $19.18 | 2024 | |
| Verrica Pharmaceuticals INC. | $18.87 | 2023 | Ycanth |
| Integra Lifesciences Corporation | $14.10 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Surgenex LLC | $13.77 | 2025 | Renograft, Pellograft, Surmatrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.